[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100565951":3},{"organization":4,"armGroups":7,"interventions":42,"overallOfficials":67,"centralContacts":72,"locations":48,"responsibleParty":77,"collaborators":79,"id":84,"slug":85,"hasResults":86,"nctId":87,"briefTitle":88,"officialTitle":88,"acronym":48,"eligibilityCriteria":89,"healthyVolunteers":86,"sex":90,"minAge":91,"maxAge":48,"enrollmentInfo":92,"targetDuration":48,"studyType":95,"phases":96,"briefSummary":99,"conditions":100,"keywords":107,"overallStatus":110,"whyStopped":48,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":48},{"fullName":5,"class":6},"Applied Biology, Inc.","INDUSTRY",[8,14,19,24,29,34,38],{"label":9,"type":10,"description":11,"interventionNames":12},"DA-001 Topical","EXPERIMENTAL","Phenylephrine 2.5% Topical + TAAR agonist",[13],"Drug: DA-001",{"label":15,"type":16,"description":15,"interventionNames":17},"Placebo","PLACEBO_COMPARATOR",[18],"Other: Placebo",{"label":20,"type":10,"description":21,"interventionNames":22},"Phenylephrine Topical","Phenylephrine 2.5% Topical (per application volume - males 5mL and females 20mL)",[23],"Drug: Phenylephrine",{"label":25,"type":10,"description":26,"interventionNames":27},"DA-001 Topical + DA-005 Oral (HIF-1α supplement)","DA-001 Topical (Phenylephrine 2.5% Topical + TAAR agonist tyramine) + DA-005 Oral (HIF-1α supplement)",[28],"Other: DA-001 Topical + DA-005 Oral (HIF-1α supplement)",{"label":30,"type":10,"description":31,"interventionNames":32},"DA-010 - Oral Phenylephrine 20 mg + DA-005 Oral (HIF-1α supplement)","Oral Phenylephrine 20 mg + DA-005 Oral (HIF-1α supplement)",[33],"Other: DA-010 - Oral Phenylephrine 20 mg + DA-005 Oral (HIF-1α supplement)",{"label":35,"type":10,"description":35,"interventionNames":36},"Phenylephrine Topical 0.25% + Intact Pro Topical",[37],"Drug: Phenylephrine Topical 0.25% + Intact Pro Topical",{"label":39,"type":10,"description":39,"interventionNames":40},"Phenylephrine + Intact Pro + DA-005 Oral (HIF-1α supplement)",[41],"Other: Phenylephrine + Intact Pro + DA-005 Oral (HIF-1α supplement)",[43,49,53,57,59,61,64],{"type":44,"name":45,"description":46,"armGroupLabels":47,"otherNames":48},"DRUG","DA-001","Phenylephrine 2.5% Topical + TAAR Agonist (GRAS) Topical Solution",[9],null,{"type":50,"name":15,"description":51,"armGroupLabels":52,"otherNames":48},"OTHER","Placebo Topical Solution",[15],{"type":44,"name":54,"description":55,"armGroupLabels":56,"otherNames":48},"Phenylephrine","Phenylephrine 2.5% Topical",[20],{"type":50,"name":25,"description":26,"armGroupLabels":58,"otherNames":48},[25],{"type":50,"name":30,"description":31,"armGroupLabels":60,"otherNames":48},[30],{"type":44,"name":35,"description":62,"armGroupLabels":63,"otherNames":48},"Phenylephrine 0.25% + Intact Pro (50% stronger)",[35],{"type":50,"name":39,"description":65,"armGroupLabels":66,"otherNames":48},"Phenylephrine 0.25% + Intact Pro (50% stronger) + DA-005 Oral (HIF-1α supplement)",[39],[68],{"name":69,"affiliation":70,"role":71},"Andy Goren, MD","University of Rome G. Marconi","STUDY_DIRECTOR",[73],{"name":69,"role":74,"phone":75,"phoneExt":48,"email":76},"CONTACT","16507040850","clinicalstudies@appliedbiology.com",{"type":78,"investigatorFullName":48,"investigatorTitle":48,"investigatorAffiliation":48,"oldNameTitle":48,"oldOrganization":48},"SPONSOR",[80,82],{"name":81,"class":6},"Follea International Limited",{"name":83,"class":6},"Daniel Alain, Inc.","100565951","phase-2-clinical-study-of-da-001-as-a-treatment-for-hair-shedding-reduction-and-hair-re-growth-100565951",false,"NCT06648850","Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-Growth","Inclusion Criteria:\n\n* Age 18 or older\n* Diagnosed with telogen effluvium\n* Willing and able to apply the treatment as directed, comply with study\n* Otherwise healthy\n* Able to give informed consent\n\nExclusion Criteria:\n\n* A medical history that may interfere with study objectives\n* Women who are pregnant, lactating, or planning to become pregnant during the study period\n* Subjects who have experienced a clinically important medical event within 90 days of the visit (e.g., stroke, myocardial infarction, etc)\n* Subjects who have known allergies to any excipient in DA-001\n* Subjects who are currently participating in another clinical study or have completed another clinical study with an investigational drug or device in the treatment area within 30 days prior to study treatment initiation\n* Subjects who have used any topical prescription medications in the treatment area within 30 days prior to study treatment initiation\n* Subjects who have had a dermatological procedure such as surgery in the treatment area within 30 days prior to study treatment initiation\n* Subject is unable to provide consent or make the allotted clinical visits","ALL","18 Years",{"count":93,"type":94},1120,"ESTIMATED","INTERVENTIONAL",[97,98],"PHASE2","PHASE3","The primary objective of the study is to assess the safety and efficacy of DA-001 as a treatment for Hair Shedding Reduction and Hair Re-Growth",[101,102,103,104,105,106],"Telogen Effluvium","Female Pattern Hair Loss","Female Pattern Hair Loss, Androgenic Alopecia","Male Pattern Baldness","Androgenetic Alopecia","Androgenetic Alopecia (AGA)",[108,109],"Hair Shedding","hair growth","NOT_YET_RECRUITING","2026-04-08",{"date":113,"type":114},"2026-04-13","ACTUAL",{"date":116,"type":94},"2026-05-01",{"date":118,"type":94},"2027-04-26",{"name":5,"class":6}]